Continue Reading Post >

Latest Tweets

#Biogen chief says market overreacted to increased enrollment in aducanumab studies; shares up 1% premarket… https://t.co/PaiYDdxadL
20th February, 2018
#Biogen shares tumble after key exec notes a changeup to pivotal aducanumab study due to ‘variability’ https://t.co/eHi5y2Fudh
16th February, 2018